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Background: The combination of the severity of pediatric-onset inﬂammatory bowel disease (IBD) phenotypes and the need for intense medical
treatment may increase the risk of malignancy and mortality, but evidence regarding the extent of the problem is scarce. Therefore, the Porto Pediatric
IBD working group of ESPGHAN conducted a multinational-based survey of cancer and mortality in pediatric IBD.
Methods: A survey among pediatric gastroenterologists of 20 European countries and Israel on cancer and/or mortality in the pediatric patient
population with IBD was undertaken. One representative from each country repeatedly contacted all pediatric gastroenterologists from each country for
reporting retrospectively cancer and/or mortality of pediatric patients with IBD after IBD onset, during 2006–2011.
Results: We identiﬁed 18 cases of cancers and/or 31 deaths in 44 children (26 males) who were diagnosed with IBD (ulcerative colitis, n ¼ 21) at
a median age of 10.0 years (inter quartile range, 3.0–14.0). Causes of mortality were infectious (n ¼ 14), cancer (n ¼ 5), uncontrolled disease activity of
IBD (n ¼ 4), procedure-related (n ¼ 3), other non-IBD related diseases (n ¼ 3), and unknown (n ¼ 2). The most common malignancies were
hematopoietic tumors (n ¼ 11), of which 3 were hepatosplenic T-cell lymphoma and 3 Ebstein–Barr virus–associated lymphomas.
Conclusions: Cancer and mortality in pediatric IBD are rare, but cumulative rates are not insigniﬁcant. Mortality is primarily related to infections,
particularly in patients with 2 or more immunosuppressive agents, followed by cancer and uncontrolled disease. At least 6 lymphomas were likely
treatment-associated by virtue of their phenotype.
(Inﬂamm Bowel Dis 2014;20:291–300)
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T he incidence of pediatric inﬂammatory bowel disease (PIBD)in European countries has risen signiﬁcantly in the past
2 decades, as shown by several recent studies.1–3 Over this same
period, medical treatment of PIBD has changed considerably with
a tendency for using more aggressive immunosuppressive medica-
tions earlier in the disease course. In addition, pediatric-onset IBD
is more often extensive, more severe, and patients have a longer
anticipated duration of disease, as compared with adults.4,5
Death and cancer from IBD in children are devastating but
fortunately rare and may be because of factors related to the
inﬂammation or those related to medical or surgical interventions.
Disease-associated cancers are usually adenocarcinomas arising
from chronic inﬂammation, whereas lymphoproliferative disor-
ders (e.g., Ebstein–Barr virus [EBV]–associated lymphomas or
hepatosplenic T-cell lymphomas [HSTCL]) have been associated
with speciﬁc treatments, most notably thiopurines.6,7 In addition,
cervical cancer and skin cancers have been recognized as adverse
events of immunosuppressive medications, including biologics.
The need to control active disease, decrease steroid exposure,
and prevent complications has led to an increased exposure to
thiopurines, biologics, and calcineurin inhibitors8–10 and hesita-
tion to combine biologics and immunomodulators for patients
who failed monotherapy.11 It is difﬁcult to assess the risk of
malignancy and mortality in small pediatric clinical trials with
short-term follow-up. Therefore, the Porto Pediatric IBD working
group of ESPGHAN conducted a multinational–based survey of
malignancy and mortality in PIBD to assess the causes of mor-
tality, the types of cancers that occur, and their association to
disease-related factors or to medical or surgical interventions.
METHODS
This is a retrospective multinational multicenter study. The
choice of a retrospective design was made based on the expected
low incidence rate of the outcomes. A 6-year period was chosen,
because it is reasonable to assume that recall bias of pediatricians
TABLE 1. National Pediatric Gastroenterologists or Pediatric Gastroenterology Centers Taking Care of Pediatric
Patients with IBD with Percentage of Active Response; Patient Numbers (Mortality and/or Cancer) per Country,
During 2006–2011
Country
Pediatric Gastroenterologists or
Centers Treating Patients with
PIBD per Country
Percentage of Pediatric
Gastroenterologist Who Actively
Replied, %
Total No.
of Patients
(n ¼ 44)
Mortality Cases
per Country
Cancer Cases
per Country
Germany 145 ped GIs 70 8 6 3
England 75 ped GIs NA 4 4 1
Wales 4 ped GIs 100 1 0 1
Scotland 10 ped GIs 100 2 1 2
Spain 115 ped GIs 90 4 3 1
Sweden 21 regions 62 4 3 1
The Netherlands 35 ped GIs 100 3 1 2
Poland 16 centers 100 3 3 1
Greece 15 centers 100 2 2 1
Czech Republic 27 ped GIs 100 2 2 0
Israel 61 ped GIs 69 2 2 0
Finland 15 ped GIs 100 2 1 1
Romania 15 ped GIs 100 2 2 0
Italy 35 ped GIs 94 2 1 1
Croatia 10 centers 100 1 0 1
Hungary 10 centers 100 1 0 1
France 27 centers 44 1 0 1
Belgium 11 centers 100 0 0 0
Switzerland 5 centers 60 0 0 0
Portugal 9 centers 100 0 0 0
Denmark 16 centers 56 0 0 0
Austria 14 ped GIs 50 0 0 0
Ped GI, pediatric gastroenterologist; NA, not available.
de Ridder et al Inﬂamm Bowel Dis  Volume 20, Number 2, February 2014
292 | www.ibdjournal.org
is minimal when probing outcomes such as mortality and cancer
within such period.
Dedicated national representatives (1 per country) of 20
European countries and Israel were appointed. The representative
contacted all pediatric gastroenterologists within each country
through e-mail requesting for possible cases at least twice (unless
all pediatric gastroenterologists had already responded on the ﬁrst
e-mail). Besides the e-mails, pediatric gastroenterology colleagues
were personally approached during national meetings.
Inclusion criteria for reported cases were patients with IBD
diagnosed before 19 years of age, who were diagnosed with any
type of malignancy or mortality after disease onset of IBD but
before the age of 19 years. To further minimize recall bias, we
limited the reported cases to the 6 years preceding the survey
(2006–2011).
For each reported case, a form was ﬁlled in and collected. A
structured form of data ascertainment was completed for each
reported case, including questions on patient characteristics,
disease history, treatments, comorbidity, type of malignancy,
and/or cause of death. In France (EPIMAD) and Germany
together with Austria (CEDATA-GPGE), national IBD registries
of malignancy and mortality have been identiﬁed and explored for
further missed cases. Patients reported outside the time frame
were excluded from analysis.
RESULTS
The 21 national representatives identiﬁed 44 children (18
with malignancy, 31 with mortality of which 5 died because of
malignancy) from 15 countries (Table 1). The percentage of the
national pediatric gastroenterology colleagues who actively re-
sponded whether they had had any cases is recorded in Table 1.
Furthermore, the national representatives assumed, because of per-
sonal communication during meetings, that all pediatric gastroen-
terologists who did not respond to the e-mails did not have any
patients ﬁtting the inclusion criteria. The exploration of the national
databases EPIMAD and CEDATA-GPGE did not reveal any addi-
tional cases. In the years 2006–2011; 7, 6, 4, 5, 3, and 16 cases
have been reported, respectively. The precise year of mortality or
development of cancer or mortality was unknown in 3 cases.
Malignancy
Patient characteristics and details of the 18 children devel-
oping a malignancy are shown in Tables 2 and 3, respectively. The
majority of patients (67%) had Crohn’s disease (CD). Eleven out of
18 (61%) had developed a lymphoma or leukemia of which 3 were
HSTCL and 3 EBV-positive lymphomas, which are typically asso-
ciated with immunosuppression. These 6 patients had all been trea-
ted with thiopurines (ranging from 12 to 96 mo) until diagnosis, but
one who had stopped thiopurines at least 3 months before HSTCL
was diagnosed. Only 1 patient had also received 3 inﬂiximab in-
fusions, 5 years before the diagnosis of cancer. One patient with
ulcerative colitis (UC) developed an adenocarcinoma of the colon
at 16 years of age after a disease duration of 13 years. He had been
diagnosed of UC at 3 years and of primary sclerosing cholangitis at
13 years of age. Another patient with UC developed cholangiocar-
cinoma at the age of 8 years, with a disease duration of 5 years,
without known primary sclerosing cholangitis. Of those who died
due to a malignancy, 4 out of 5 malignancies are likely associated
with IBD or the treatment received (HSCTL [n ¼ 2], EBV-positive
lymphoma [n ¼ 1], and 1 adenocarcinoma).
All 3 patients who developed HSTCL were males and had
exposure to thiopurines ranging from 32 to 108 months; none
received a biologic. Two of the 3 EBV-associated lymphomas
received thiopurines before diagnosis, whereas the medical
therapy for the third patient was not available.
Mortality
We identiﬁed 31 fatalities among patients during follow-up,
and patient characteristics and details are shown in Tables 4 and 5,
respectively. The majority of patients (61%) had UC.
TABLE 2. Patient Characteristics of Pediatric IBD Cases
Who Developed Cancer Before the Age of 19 Years,
During the Period 2006–2011 (n ¼ 18)
No. of Patients (%)
Gender
Male 14 (78)
Female 4 (22)
Age at diagnosis of IBD, median (IQR), yr 12 (3–15)
Type of IBD
CD 12 (67)
UC 4 (22)
IBD-U 1 (6)
Unknown 1 (6)
Disease duration (yr) 5 (2.0–6.0)
Age at diagnosis of cancer, yr 16.0 (14.0–17.0)
Medication (last 3 mo)
Steroids 4 (22)
Thiopurines 12 (67)
Methotrexate 1 (6)
Biological 2 (11)
Calcineurin inhibitor 1 (6)
Combination therapy (thiopurine and biological) 1 (6)
Medication (any time before 3 mo)
Steroids 14 (78)
Thiopurines 13 (72)
Biological 2 (11)
Calcineurin inhibitor 1 (6)
Methotrexate 0 (0)
Duration of immunosuppression (mo) 29 (8–60)
Rates or medians (IQR) are presented as appropriate.
IBD-U, inﬂammatory bowel disease unclassiﬁed.
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TABLE 3. Reported Pediatric IBD Cases Who Developed Cancer Before the Age of 18 Years, During the Period 2006–2011 (n ¼ 18)
Age at Diagnosis of IBD
(yr)/Sex, Type of IBD Type of Cancer
Age at Development
of Cancer (yr) Mortality
Immunosuppressants Last
3 mo (Duration)/Other Drugs
Biologicals Last
3 mo (Duration)
Calcineurin Inhibitor
Last 3 mo (Duration)
1 3/F, UC Cholangiocarcinoma 8 No Thiopurine (18) No No
2 2/M, UC HSTCL 9 No Steroids, thiopurine (72) No No
3 12/F, CD Acute lymphoid leukemia 13 No Steroids, thiopurine (12) No No
4 8/M, CD Primitive neuroectodermal tumor 14 Yes Steroids, thiopurine (12) No Yes (9)
5 2/M, IBD-U HSTCL 15 Yes Thiopurine (108), sulfasalazine No Yes (18)
6 10/M, CD EBV-associated lymphoma 15 Yes Steroids, thiopurine (12) No Yes (25)
7 15/M, CD Acute myeloid leukemia 15 No Thiopurine (10) No No
8 14/M, CD Medulloblastoma 15 No No Yes (18) No
9 10/F, CD Pilocytic astrocytoma of cerebellum 15 No Methotrexate (30) No No
10 3/M, UC Adenocarcinoma of colon 16 Yes Steroids, thiopurine (240) Yes (24) Yes (16)
11 15/M, CD Hodgkin’s lymphoma 16 No Thiopurine (2) No No
12 15/M, CD EBV-positive Hodgkin-like lymphoma 16 No Thiopurine (21) No No
13 12/M, CD Hodgkin lymphoma 16 No Thiopurine (48) No No
14 9/M, CD EBV-associated lymphoma 17 No Thiopurine (96) Unknown Unknown
15 14/M, CD Basal cell carcinoma 17 No No Yes (24) No
16 17/M, CD Hodgkin lymphoma 17 No Thiopurine (3) No No
17 16/M, CD Chromophobic renal carcinoma 17 No Steroids, mesalamine No No
18 15/M, CD HSTCL 18 Yes Steroids, thiopurine (32) No Yes (8)
IBD-U, inﬂammatory bowel disease unclassiﬁed.
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The underlying cause for the infectious-related mortality
cases (n ¼ 14) included sepsis (n ¼ 7, 47%) and opportunistic
infections (n ¼ 4, 29%), such as candida and varicella virus.
Cases of tuberculosis or Pnarmocystis jimveci pneumonia were
not diagnosed.
Medications used in the 3 months preceding mortality of
the 14 children who died because of infectious causes were given
monotherapy with steroids (n ¼ 1, 7%) or thiopurine (n ¼ 1, 7%),
combination therapy of 2 immunomodulators (n ¼ 11, 73%) (ste-
roids and thiopurine [n ¼ 4], steroids and MTX [n ¼ 1], steroids
and biologic [n ¼ 1], thiopurine and biologic [n ¼ 2], MTX and
biologic [n ¼ 1], and thiopurine and calcineurin inhibitor [n ¼ 2])
or combination therapy of even 4 immunomodulators (n ¼ 1, 7%)
(steroids, thiopurine, biologic, and a calcineurin inhibitor).
Three out of the 14 patients (21%) were treated with total
parenteral nutrition through a central venous access. All these
patients had CD and had been treated with a biologic, in
combination with either steroids, thiopurine, or MTX.
Three out of 5 patients who died due to cancer were
probably treatment-related, these resulted from HSTCL (n ¼ 2)
and EBV-positive lymphoma (n ¼ 1). One patient died due to
a malignancy, which probably was disease-related, being colonic
adenocarcinoma. The ﬁfth patient had a primitive neuroectoder-
mal tumor.
Four patients died because of uncontrolled disease activity
as follows: 1 patient died because of complications of CD, which
were not further speciﬁed; 1 patient developed toxic megacolon
and sepsis; and 1 multiorgan failure (we could not ascertain if
sepsis was present). The latter 2 patients were nonadherent to their
medication. The fourth patient developed cardiomyopathy and
a fatal thromboembolic event.
Three patients died because of procedure-related compli-
cations, including a perforation during surgical colectomy to treat
toxic megacolon, pericardial tamponade during anesthesia, and
a sepsis and cerebral thrombosis, shortly after total colectomy.
DISCUSSION
In the era of increased use of biologics and immunosup-
pressive medications, development of management strategies for
IBD requires evidence for an effect of treatment and adverse
outcomes, so that risk/beneﬁt can be applied to the decision
making process by clinicians. Biologics and immunosuppressants
are used in combination quite frequently, whether combination
therapy is superior to any individual therapy is still a matter of
debate.12 Recent large studies have shown that early immunosup-
pression decreases the risk for stricturing and penetrating disease
and the need for surgery over 10 years of follow-up.13 Although
data regarding the risk for disease-associated complications such
as stricturing, penetrating, or perianal disease are available, data
regarding the risk for the most severe complications such as can-
cer and fatal disease are still lacking in children.
Malignancy
At least 6 lymphomas (HSTCL or EBV-positive lym-
phoma) were likely treatment-associated, by virtue of their
phenotype. Pediatricians using immunosuppressants (typically
thiopurines often in combination with anti-TNFs, although the
patients developing HSTCL or EBV-positive lymphoma within
this cohort were all treated with thiopurine monotherapy) should
be aware of this rare but very serious complication.
Disease-related malignancies were likely in 2 patients who
developed adenocarcinomas of the gastrointestinal tract. The third
most common malignancy after HSTCL and EBV-positive
lymphoma was Hodgkin lymphoma, which is common in
adolescents regardless of IBD. The lack of a control group makes
it impossible to elucidate how many of the Hodgkin cases are
disease-speciﬁc.
TABLE 4. Patient Characteristics of Pediatric Patients
with IBD Who Died (Total n ¼ 31)
No. of Patients (%)
Gender
Male 17 (55)
Female 14 (45)
Age at diagnosis IBD, median (IQR), yr 8.9 (3–14)
Type of IBD
CD 9 (29)
UC 19 (61)
IBD-U 2 (6)
Unknown 1 (3)
Disease duration, median (IQR), yr 3.0 (2.0–8.0)
Age at moment of death, median (IQR), yr 14.6 (13.1–16.0)
Cause of death
Infection 14 (45)
Cancer 5 (16)
Other disease 3 (10)
Uncontrolled disease activity 4 (13)
Procedure-related complication 3 (10)
Unknown 2 (6)
Medication (last 3 mo)
Steroids 19 (61)
Thiopurines 18 (58)
Methotrexate 2 (6)
Biological 8 (26)
Calcineurin inhibitor 7 (23)
Combination therapy 19 (61)
Medication (previous)
Steroids 25 (81)
Thiopurines 21 (68)
Methotrexate 6 (19)
Biological 8 (26)
IBD-U, inﬂammatory bowel disease unclassiﬁed.
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TABLE 5. Pediatric IBD Cases Who Died Before the Age of 18 Years During the Period 2006–2011 (n ¼ 31)
Age at Diagnosis of IBD
(yr)/Sex, Type of IBD Cause of Mortality
Age at
Death, yr
Immunosuppressants and
Steroids Last 3 mo
(Duration)/Other Drugs
Biologicals Last 3
mo (Duration)
Calcineurin Inhibitor
Last 3 mo (Duration)
1 1/M, UC Decompensation of maple syrup disease,
neurological complications, multiorgan failure
2 Steroids, thiopurine 4) No Yes (2)
2 3/M, UC Toxic megacolon, sepsis. Nonadherence to
medication
5 Mesalamine No No
3 2/M, UC Shock and severe dehydration, cause unknown 5 Steroids, thiopurine (2), antibiotics No No
4 7/F, UC Sepsis 8 Steroids, thiopurine (6) No No
5 7/F, UC Acute myocarditis 9 Steroids, granulocyte aferesis No No
6 2/F, CD Complications of CD 10 Steroids, thiopurine (.3), methotrexate Yes (duration
unknown)
Yes (duration unknown)
7 0.5/M, IBD-U Sepsis 13 Steroids, total parenteral nutrition,
antibiotics
No No
8 9/F, UC Chickenpox 13 Steroids, thiopurine (48) No Yes (24)
9 5/M, CD E. coli and candida sepsis (CVL) 13 Steroids, thiopurine Yes (.3) No
10 6/F, UC Postoperative complication after colectomy 14 Steroids No No
11 8/M, CD Primitive neuroectodermal tumor 14 Steroids, thiopurine (12) No No
12 14/F, UC Ventricular ﬁbrillation, cause unknown 14 Steroids, thiopurine (.3) No No
13 14/F, UC Toxic megacolon, perforation 14 Steroids, antibiotics No No
14 10/M, CD Multiorgan failure, malnutrition, intracranial
ischemia. Nonadherence to medication
14 Steroids, mesalamine, ursodeoxycholic
acid, probiotics
No No
15 11/F, CD Pericardial tamponade during anesthesia 14 Steroids, thiopurine (.3) Yes (duration
unknown)
Yes (,3)
16 7/M, UC Uncontrolled diarrhea, exact cause of death
unknown
14 Steroids, thiopurine (2), mesalamine No No
17 2/M, IBD-U HSTCL 15 Thiopurine (108), sulfasalazine No No
18 13/M, UC Sepsis 15 Steroids, thiopurine (6) antibiotics Yes (1 dose) Yes (1)
19 12/F, UC Meningitis 15 Steroids, thiopurine (36) No Yes (12)
20 12/F, UC ARDS (pneumonia), CMV colitis, and CMV-
pneumonia
15 Steroids, thiopurine (.3), ganciclovir No Yes (duration unknown)
21 10/M, CD EBV-associated lymphoprolipherative disease 15 Steroids, thiopurine (12) No No
22 14/F, CD Multiorgan failure 16 Thiopurine (.3), mesalamine No No
23 14/F, UC Bronchopneumonia, possibly related to morphine
use and aspiration
16 Steroids, thiopurine (.3) Yes (.3) No
24 3/M, UC Adenocarcinoma of colon 16 Steroids, thiopurine (240) Yes (48) Yes (24)
25 3/M, CD Sepsis, intracranial hemorrage 16 Steroids, thiopurine (unknown), total
parenteral nutrition, antbiotics
No No
26 8/M, CD Staph coag neg sepsis (CVL), pulmonary aspergillus 16 Thiopurine (.3), total parenteral
nutrition
Yes (duration
unknown)
No
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Interestingly enough, none of the malignancy-associated
fatalities occurred during the use of a biologic. This may reﬂect
the less frequent use and access in pediatric patients to biologics
during the study period.
Although assuming signiﬁcant underreporting bias (see
limitations), IBD-associated malignancies seem rare. This probably
reﬂects age-related risk, but also that disease- and therapy-associated
malignancies require prolonged exposure to inﬂammation or drugs
to occur. This was illustrated in a systematic review on the natural
history of pediatric-onset IBD,14 showing that cancers were reported
in only 14 patients within 11 clinic/hospital-based studies. Twelve
out of these 14 (86%) patients developed cancer after the age of 19
years. Six out of the 14 patients had CD, and they all developed
colonic or small bowel adenocarcinoma except one who developed
metastatic breast carcinoma, whereas 8 out of the 14 patients had
UC, and they all developed colonic adenocarcinoma except one
who developed cholangiocarcinoma.
The CESAME study on lymphoproliferative disorders in
patients with IBD found an incidence of 9 per 10,000 patient-
years among 5867 patients treated with thiopurines, most were the
EBV-positive lymphoproliferative type.15 The maximum risk was
associated with older age and longer duration of disease.
A large Dutch study in 17,834 patients with IBD identiﬁed
44 lymphomas (only adult patients, diagnosed at mean age of
54 yr, only 1 patient with pediatric-onset CD at age of 17 yr),
resulting in a relative risk of 1.27 (95% conﬁdence interval, 0.92–
1.68).16 Nineteen of 44 patients (43%) were exposed to thiopur-
ines. A total of 92% of patients (11/12) with EBV-positive lym-
phoma were treated with thiopurines compared with only 19%
patients (4/21) with EBV-negative lymphoma, suggesting a strong
relation between EBV-positive lymphoma and thiopurine use.
This is in accordance with the EBV-positive lymphoma cases in
our study cohort. Although there is evidence that IBD therapies in
adult patients increase the risk of certain malignancies in patients
with both CD and UC (lymphomas, HSTCL, and non melanoma
skin cancer), the absolute incidence rate of these malignancies is
low.17 For example, the absolute incidence of non-Hodgkin’s
lymphoma is estimated to be 6.1 per 10,000 patient-years while
on combination therapy of an immunosuppressor and anti-TNF in
patients with CD in a meta-analysis.18 Male patients under
35 years seem to be at particular risk of HSTCL, especially when
exposed to either a thiopurine or thiopurine in combination with
anti-TNF therapy. However, the estimated absolute risk for men
,35 years on combination therapy still is extremely low, being
1:3534.19 The data from our study also seem to show that the risk
is low, because only 3 patients with HSTCL were identiﬁed dur-
ing a 6-year period in 20 countries, although thiopurine use was
common during this time period.
In children, the risk for these malignancies seems even lower,
but it is unknown whether it increases with age. A retrospective
study on children and young adults with IBD found only 2 cases of
lymphomas during childhood (males at age 12 and 18 yr, both
treated with thiopurines) among 1374 patients with a mean follow-
up of 4.8 years.20 The incidence among thiopurine-exposed patientsTA
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was 4.5 per 10,000 patient-years. These ﬁndings demonstrate that
fatal events are rare during childhood. However, the life-time risk is
unknown, and thus the question to what extent drug-related risk
should dominate treatment decisions in this age group remains
unanswered.
Mortality
We found that mortality is uncommon and is primarily
related to the occurrence of infections. It is striking that the
majority of patients were diagnosed with UC, although UC is
considered to be curable by colectomy. Nine out of 19 (47%)
patients with UC died because of an infectious complication.
These fatalities may have been prevented by earlier surgical
intervention when intensiﬁed medical treatment is ineffective
(Fig. 1). In addition, this could serve as an argument against
sequential therapy in acute severe colitis (calcineurin inhibitors
after inﬂiximab or vice versa) instead of colectomy, as suggested
in the recent ECCO/ESPGHAN guideline.21
Most of the patients with fatal infections were treated with
2 or more immunomodulators (n ¼ 12, 86%), although this was
only the case for 1 patient who developed cancer and for 6 (35%)
patients who died because of causes other than infections. This
illustrates the increased risk of infectious complications in patients
on combination of immunomodulatory therapy.22 Three of these
13 patients were at risk of infections by virtue of a central venous
catheter. Whenever possible, enteral instead of parenteral nutrition
should be used because a central venous catheter in immune-
suppressed patients clearly is a risk.
To prevent opportunistic infections in children with IBD on
immunosuppressive therapy, the recently published guidelines
should be followed.23,24 These guidelines include assessment and
correction of the patient’s nutritional status because malnutrition
is a concomitant risk factor for an opportunistic infection and
optimization of immunizations before the initiation of immuno-
suppressive agents. For children with triple immunosuppressive
therapy, cotrimoxazole prophylaxis against P. jiroveci is advised.
Limitations
This report is the ﬁrst to assess major risks of PIBD in
a large population, but it is not without limitations. The ﬁrst
limitation is the retrospective design of the study. It is almost
certain that the reported cases are not a full list of fatalities and
cancer in the included countries during the study period, but it is
impossible to assess the rate of underreporting. Physicians treating
pediatric patients with IBD may not have been contacted or may
have not cooperated, but patients may have been treated by adult
gastroenterologists at an age younger than 19 years as shown in
the EUROKIDS registry, which makes it likely that many patients
with IBD from the age of 15 years are diagnosed and treated by
adult gastroenterologists.25
We could not calculate if children with IBD were at
increased risk for cancer or mortality because of the lack of
a denominator (the number of children with IBD in each country
and the risk for mortality in the underlying population).
Patients who died of other causes and did not show up for
follow-up may have been missed because of lack of awareness.
An additional limitation has to do with the age limitations within
the study design. We assessed the burden of serious adverse
outcome by the age of 19 years. However, it is plausible to
assume that many developed a malignancy or died after that age,
FIGURE 1. Causes of fatalities in pediatric IBD. IBD-U, inﬂammatory bowel disease unclassiﬁed.
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which still could be a consequence of the disease or treatment
prescribed during childhood. In addition, we did not ascertain the
denominator of treated PIBD during the same period. However, it
was not the aim of the study to elucidate exact rates of adverse
events but to bring to the attention of practicing gastroenterolo-
gists that serious adverse events of both the disease and treatment
do occur and to highlight the ratio between these 2 competing
groups. Although we do not know how many of the cancer cases
are unrelated to the disease, at least 6 of the reported malignancies
were clearly related to the disease or its treatment and probably
some of the others also.
Taken together, the true case ascertainment of grave
outcomes during childhood is probably higher than reported here.
First, it is important to note that at least half of mortality cases
reported were treatment-related, whereas approximately 1/6 were
disease-related and 1/10 were procedure-related. Second, only
2 cases of mortality were because of surgical complications in
UC, and more were related to uncontrolled disease or immuno-
suppressant treatment. However, more patients will have received
medical than surgical treatment, which makes these numbers
difﬁcult to compare head-to-head. Still, it seems important to
consider colectomy in every case of resistant disease requiring
multiple immunosuppressant medications.26
Many recent studies have focused on speciﬁc outcomes
such as surgery, infection, or lymphomas; and depending on the
outcome, advocate either earlier immunomodulation to prevent
complicated disease and surgery or less immunomodulation to
prevent medication-associated adverse events. Reports that just
focus on cancer but not on severe disease outcome induce a bias.
Because there is a lack of evidence-based guidance, physicians
need to weigh all the different risks and propose a comprehensive
strategy for young patients with a severe disease burden.15,21
We clearly need larger cohorts with prospective data
collection to understand the risk of withholding treatment versus
overtreatment, and this report should be regarded as a preliminary
attempt to address the complex problem of the very rare but
severe outcomes of PIBD.
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